Counter-claims by an ex-Stryker sales rep can stand in a poaching dispute involving Biomet, a federal judge rules.
Here's a look at some of the top legal news stories for medical device companies this week: Judge nixes alleged settlement in Stryker, Biomet poaching spat; Boston Scientific loses bids to exclude testimony in pelvic mesh trials; Occlutech claims another win over St. Jude Medical; Align Tech declares a 'total win' as federal circuit reverses ITC ruling; Report: Medtronic shareholder sues to block Covidien merger
A Michigan federal judge denies a settlement in the poaching spat between Biomet and Stryker and a pair of ex-Stryker sales reps.
Here's a look at some of the top legal news stories for medical device companies this week: Guidant can't slip breach-of-contract charges in Johnson & Johnson suit; Biomet reveals SEC subpoena over alleged 'improprieties' in Brazil, Mexico; Appeals court upholds Retractable Technologies win over Becton Dickinson; Board suspends ex-PricewaterhouseCoopers accountant over ArthroCare scandal; Covidien's Nellcor and CAS Medical settle dispute for $275k
, Becton Dickinson & Co.
, Boston Scientific
, CAS Medical Systems Inc.
, Dept. of Justice (DOJ)
, Guidant Corp.
, Johnson & Johnson
, Public Company Accounting Oversight Board
, Retractable Technologies Inc.
, Securities & Exchange Commission (SEC)
, Abbott Laboratories
Biomet puts black ink back in the ledger for its fiscal 4th quarter and 2014, reporting double-digit adjusted profit increases for both periods.
Biomet said yesterday that it put black ink back into its books for the fiscal 4th quarter and 2014, with adjusted profits rising by double digits.
Here's a look at some of the top regulatory stories for medical device companies this week: Covidien taps integration chief to navigate Medtronic merger; Zimmer, Biomet appoint integration team; Thoratec inks $75M deal for Apica Cardiovascular; FTC wants more from Zimmer, Biomet on merger; Johnson & Johnson closes Ortho-Clinical Diagnostics sale
More than 2 years after inking a $22 million deal to settle charges that it violated the Foreign Corrupt Practices Act, Biomet says the SEC issued a subpoena over alleged "improprieties" in Brazil and Mexico.